AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late ... beat Symbicort over 24 weeks, with performance ...
DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...
Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
News Medical on MSN4mon
Widespread inhaler misuse in COPD patients: Need for trainingImage Credit: AtlasStudio / Shutterstock.com Chronic obstructive pulmonary disease (COPD ... hours of admission. The ...
HealthDay on MSN9d
Study Compares Single-Inhaler Triple Therapies for Treatment of COPDFor patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback